Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third leading cause of cancer deaths, and while mortality has largely improved in the developed world, five-year survival for metastatic disease remains dismally low at only 15%. Fortunately, nearly a dozen targeted therapies and immunotherapies have been FDA approved...
Main Authors: | Prashanth Rawla, Adam Barsouk, Andreas V. Hadjinicolaou, Alexander Barsouk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3271/7/8/83 |
Similar Items
-
Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers
by: Adam Barsouk, et al.
Published: (2019-09-01) -
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
by: Prashanth Rawla, et al.
Published: (2019-01-01) -
Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01) -
Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
by: Emmanouil Damilakis, et al.
Published: (2020-04-01) -
METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)